Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours.

[1]  P. Laird,et al.  Hypomethylation and hypermethylation of DNA in Wilms tumors , 2002, Oncogene.

[2]  P. Holt,et al.  Differential Patterns of Methylation of the IFN-γ Promoter at CpG and Non-CpG Sites Underlie Differences in IFN-γ Gene Expression Between Human Neonatal and Adult CD45RO− T Cells1 , 2002, The Journal of Immunology.

[3]  P. Ainsworth,et al.  Allele-specific non-CpG methylation of the Nf1 gene during early mouse development. , 2001, Developmental biology.

[4]  Jeannie T. Lee,et al.  CTCF, a Candidate Trans-Acting Factor for X-Inactivation Choice , 2001, Science.

[5]  M. Wolter,et al.  Oligodendroglial Tumors Frequently Demonstrate Hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) Tumor Suppressor Genes , 2001, Journal of neuropathology and experimental neurology.

[6]  R. Mirsky,et al.  Developmental regulation and overexpression of the transcription factor AP‐2, a potential regulator of the timing of Schwann cell generation , 2001, The European journal of neuroscience.

[7]  K. Leroy,et al.  Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. , 2001, Archives of dermatology.

[8]  D. Gutmann,et al.  NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. , 2001, The American journal of pathology.

[9]  X. Estivill,et al.  Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. , 2000, Human molecular genetics.

[10]  D. Troost,et al.  Microsatellite instability and promoter methylation as possible causes of NF1 gene inactivation in neurofibromas , 2000, European Journal of Human Genetics.

[11]  Y. Bang,et al.  Methylation of specific CpG sites in the promoter region could significantly down‐regulate p16INK4a expression in gastric adenocarcinoma , 2000, International journal of cancer.

[12]  D. Cooper,et al.  Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours , 2000, Human Genetics.

[13]  R. Zarnegar,et al.  The repressive function of AP2 transcription factor on the hepatocyte growth factor gene promoter. , 2000, Biochemical and biophysical research communications.

[14]  A. Bird,et al.  Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Upadhyaya,et al.  A search for evidence of somatic mutations in theNF1 gene , 2000, Journal of medical genetics.

[16]  D. Louis,et al.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. , 1999, The American journal of pathology.

[17]  Shiva M. Singh,et al.  Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors , 1999, Oncogene.

[18]  M. Ruggieri.  The different forms of neurofibromatosis , 1999, Child's Nervous System.

[19]  D. Lenartz,et al.  Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas , 1999, Acta Neuropathologica.

[20]  J. Woodruff.  Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. , 1999, American journal of medical genetics.

[21]  A. Guha,et al.  Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. , 1999, Surgical neurology.

[22]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[23]  M. Szyf,et al.  Concurrent Replication and Methylation at Mammalian Origins of Replication , 1998, Molecular and Cellular Biology.

[24]  F. O'Malley,et al.  CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site , 1998, Oncogene.

[25]  X. Estivill,et al.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. , 1997, American journal of human genetics.

[26]  Stephen B. Baylin,et al.  Mapping Patterns of CpG Island Methylation in Normal and Neoplastic Cells Implicates Both Upstream and Downstream Regions inde Novo Methylation* , 1997, The Journal of Biological Chemistry.

[27]  A. Olek,et al.  A modified and improved method for bisulphite based cytosine methylation analysis. , 1996, Nucleic acids research.

[28]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Susan J. Clark,et al.  CpNpG methylation in mammalian cells , 1995, Nature Genetics.

[30]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. Collins,et al.  DNA sequences in the promoter region of the NF1 gene are highly conserved between human and mouse. , 1994, Genomics.

[32]  J. Cole,et al.  Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation , 1993, Journal of neuroscience research.

[33]  T. Sakai,et al.  CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. , 1993, Oncogene.

[34]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[35]  M. Comb,et al.  CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2 , 1990, Nucleic Acids Res..